HighTower Advisors’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

HighTower Advisors’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-6	Closed	-$14K	–	3711
2022 Q4	$14K	Sell	6 -3	-33%	-$10.5K	﹤0.01%	3158
2022 Q3	$37K	Buy	9 +3	+50%	+$11.8K	﹤0.01%	2921
2022 Q2	$14K	Hold	6	–	–	﹤0.01%	3041
2022 Q1	$21K	Sell	6 -1	-14%	-$4.3K	﹤0.01%	3163
2021 Q4	$45K	Hold	7	–	–	﹤0.01%	3035
2021 Q3	$67K	Buy	7 +1	+17%	+$8.59K	﹤0.01%	2906
2021 Q2	$65K	Hold	6	–	–	﹤0.01%	2863
2021 Q1	$123K	Hold	6	–	–	﹤0.01%	2718
2020 Q4	$36K	Buy	6 +1	+20%	+$3.92K	﹤0.01%	2437
2020 Q3	$18K	Hold	5	–	–	﹤0.01%	2379
2020 Q2	$20K	Buy	+5	New	+$16.6K	﹤0.01%	2267
2016 Q3	–	Hold	0	–	-$24K	–	1967
2016 Q2	–	Hold	0	–	–	–	1677
2016 Q1	–	Hold	0	–	–	–	1975
2015 Q4	–	Hold	0	–	–	–	1898
2015 Q3	–	Hold	0	–	–	–	1760
2015 Q2	–	Hold	0	–	-$73K	–	1737
2015 Q1	–	Hold	0	–	–	–	1518
2014 Q4	–	Hold	0	–	–	–	1521
2014 Q3	–	Hold	0	–	–	–	1451
2014 Q2	–	Hold	0	–	–	–	1480

Other funds holding SEEL

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UIC

Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

MWM

Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HighTower Advisors's SEEL Position: Q1 2023 in Review

HighTower Advisors sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q1 2023, closing a stake of 6 shares — an estimated $14K sold.

HighTower Advisors first reported a position in SEEL in Q2 2020 and held it in 11 quarters. The position peaked at $123K in Q1 2021. 60 funds tracked by Wall St. Rank hold SEEL as of Q1 2023.

HighTower Advisors reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
HighTower Advisors sold 6 Seelos Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $14K.
HighTower Advisors first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2020 and held it in 11 quarters.
HighTower Advisors's Seelos Therapeutics, Inc. Common Stock position peaked at $123K in Q1 2021.
60 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q1 2023.

Based on HighTower Advisors's 13F filing for Q1 2023, filed 12 May 2023.